PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Ellis, Matthew J.
TI  - Harnessing Genomics and Molecular Profiling in ER-Positive BC for New Therapies
DP  - 2014  01
TA  - MD Conference Express
PG  - 4--5
VI  - 14
IP  - 56
4099  - http://mdc.sagepub.com/content/14/56/4.short
4100  - http://mdc.sagepub.com/content/14/56/4.full
AB  - Genomic analysis and molecular profiling identified mutations and translocations in ER+ breast cancer that are targets for genome-directed therapeutics. ESR1 mutations and translocations contribute to endocrine therapy resistance. Novel pharmacologic approaches have successfully treated ESR1 Y537 mutation-driven resistance, mutant HER2 tumors, and wild-type RB and TP53 tumor suppressor function in preclinical and clinical work.